Published • loading... • Updated
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026
The investigator-initiated trial reported no recurrences among 10 infused patients and a manageable safety profile, with one minimal residual disease case turning negative.
Summary by News-Graphic.com
7 Articles
7 Articles
Appalachian News-Express+6 Reposted by 6 other sources
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026
SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of the investigator-initiated trial (CT041-CG4010, NCT06857786) in China of satricabtagene autoleucel…
Coverage Details
Total News Sources7
Leaning Left0Leaning Right0Center6Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
